Dr. Reddy's Laboratories Limited or ADMA Biologics, Inc.: Who Invests More in Innovation?

Dr. Reddy's vs. ADMA: A Decade of R&D Investment

__timestampADMA Biologics, Inc.Dr. Reddy's Laboratories Limited
Wednesday, January 1, 2014951701412402000000
Thursday, January 1, 2015701594617449000000
Friday, January 1, 2016768823817834000000
Sunday, January 1, 2017622958719551000000
Monday, January 1, 2018392612018265000000
Tuesday, January 1, 2019234384815607000000
Wednesday, January 1, 2020590701315410000000
Friday, January 1, 2021364606016541000000
Saturday, January 1, 2022361376417482000000
Sunday, January 1, 2023330000019381000000
Monday, January 1, 202422873000000
Loading chart...

Igniting the spark of knowledge

Innovation Investment: A Tale of Two Companies

In the competitive world of pharmaceuticals, innovation is key. Dr. Reddy's Laboratories Limited and ADMA Biologics, Inc. are two companies that have taken different paths in their investment in research and development (R&D) over the past decade. From 2014 to 2023, Dr. Reddy's consistently outspent ADMA Biologics, with R&D expenses peaking at nearly $19.4 billion in 2023, a staggering 1,900% more than ADMA's highest expenditure of approximately $9.5 million in 2014. This significant difference highlights Dr. Reddy's commitment to innovation, despite fluctuations in their annual spending. Meanwhile, ADMA Biologics has shown a more conservative approach, with a noticeable decline in R&D investment over the years. As we look to the future, the question remains: will ADMA Biologics increase its investment to compete with industry giants like Dr. Reddy's?

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025